Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy

Cornelia Dähnrich, Sandra Saschenbrecker, Iva Gunnarsson, Wolfgang Schlumberger, Pierre Ronco, Hanna Debiec

To cite this version:
Cornelia Dähnrich, Sandra Saschenbrecker, Iva Gunnarsson, Wolfgang Schlumberger, Pierre Ronco, et al.. Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy. Kidney International Reports, Elsevier, 2020, 5 (2), pp.182-188. 10.1016/j.ekir.2019.11.008. hal-02486081

HAL Id: hal-02486081
https://hal.sorbonne-universite.fr/hal-02486081
Submitted on 20 Feb 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy

Cornelia Dähnrich\textsuperscript{1}, Sandra Saschenbrecker\textsuperscript{1}, Iva Gunnarsson\textsuperscript{2,3}, Wolfgang Schlumberger\textsuperscript{1}, Pierre Ronco\textsuperscript{4,5,6} and Hanna Debiec\textsuperscript{5,6}

\textsuperscript{1}Institute for Experimental Immunology, EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany; \textsuperscript{2}Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; \textsuperscript{3}Rheumatology, Karolinska University Hospital, Stockholm, Sweden; \textsuperscript{4}Department of Nephrology (Nephrology Day Hospital), Tenon Hospital, Paris, France; \textsuperscript{5}Sorbonne Université, UPMC University Paris 06, Paris, France; and \textsuperscript{6}Institut National de la Santé et de la Recherche Médicale (INSERM) UMR_S1155, Paris, France

\textbf{Introduction:} Autoantibodies against the M-type phospholipase A2 receptor (PLA2R) are important markers in the diagnosis and monitoring of primary membranous nephropathy (pMN). For the detection of anti-PLA2R autoantibodies, a standardized recombinant cell-based indirect immunofluorescence assay (RC-IFA) and enzyme-linked immunosorbent assay (ELISA) are widely used, the former providing higher sensitivity but lacking a finely graduated quantification of antibody titers. In this study, we evaluated the diagnostic performance characteristics of a novel standardized chemiluminescence immunoassay (ChLIA) by comparison with the established anti-PLA2R test systems.

\textbf{Methods:} Sera from 155 patients with biopsy-proven pMN and 154 disease controls were analyzed for autoantibodies against PLA2R by the novel ChLIA as well as by ELISA and RC-IFA.

\textbf{Results:} The clinical sensitivity of the ChLIA (83.9\%) was higher compared with ELISA (73.5\%) and equaled that of RC-IFA (83.2\%), at similar specificities (\(\geq 99.4\%\)). Among ELISA-negative pMN samples, ChLIA and RC-IFA yielded positive results in 39.0\% and 36.6\%, respectively. The qualitative agreement amounted to 94.5\% (ChLIA vs. ELISA) and 99.4\% (ChLIA vs. RC-IFA).

\textbf{Conclusion:} The novel anti-PLA2R ChLIA outperforms the ELISA in detecting patients with pMN and demonstrates almost perfect agreement with RC-IFA. It thus presents a promising alternative tool for accurate anti-PLA2R testing, with the advantage of rapid turnaround times and fully automated random-access processing.

Kidney Int Rep (2020) 5, 182–188; https://doi.org/10.1016/j.ekir.2019.11.008

\textbf{KEYWORDS:} anti-PLA2R; autoantibody; chemiluminescence immunoassay; membranous nephropathy; phospholipase A2 receptor

© 2019 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
RC-IFA at very high specificity, the ELISA lags slightly behind in sensitivity, particularly in cases of therapeutic or spontaneous remission.6,7

Fast access to test results is crucial in clinical practice because early diagnosis and immediate immunotherapy may be life-saving in autoimmune pathologies. Therefore, diagnostic laboratories are increasingly shifting to fully automated random-access systems with focus on bead-based chemiluminescence technology.8

The objective of this study was to evaluate the performance characteristics of a novel standardized anti-PLA2R ChLIA, and to determine if this assay can close the sensitivity gap between ELISA and RC-IFA.

METHODS

Patients and Samples

The study included 155 serum samples from patients with pMN who were referred to the INSERM Unit UMR_S1155 at Tenon Hospital (Paris, France). The clinical diagnosis of pMN was supported by histopathology of kidney biopsy4,9 in the absence of associations suggestive of secondary MN. All sera were sampled at around the time of biopsy in nephrotic patients with active disease. Moreover, 154 disease control sera were collected from patients with other biopsy-proven glomerular diseases and systemic autoimmune disorders (Table 1). Control samples were obtained from INSERM Unit UMR_S1155 (Paris, France) and the Department of Rheumatology, Karolinska University Hospital (Stockholm, Sweden). Individual and ethical approval was not mandatory, as patient data and samples were used anonymously.

Immunassays

The anti-PLA2R ChLIA (EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany) is based on magnetic beads coated with recombinant human PLA2R1 that was expressed in human embryonic kidney cells and purified as described previously.6 The assay was performed fully automatically on a random-access analyzer (EUROIMMUN). All assay reagents were contained in a reagent cartridge, including PLA2R-coated beads, acridinium ester-conjugated anti-human IgG secondary antibodies (tracer), sample buffer, and diluent. Within the device, sample buffer and beads were transferred into a cuvette and patient sample was added at a dilution of 1:40. After 10 minutes at 37 °C, unbound antibodies were removed by repeated magnetic force-mediated sedimentation and washing of the beads. Acridinium ester-conjugated anti-human IgG was then added and allowed to bind to the immobilized antibodies for 10 minutes at 37 °C. The beads were sedimented and washed to remove unbound conjugate, followed by the addition of alkaline hydrogen peroxide to trigger the emission of light. The luminescence output from this reaction, which is directly proportional to the amount of anti-PLA2R bound to the antigen-coated beads, was measured luminometrically in relative light units over 10 seconds. Using a predefined lot-specific master curve and integrating the results of 2 calibrators, the system generated a standard curve adapted to the device in use. Based on this standard curve, the results were automatically converted from relative light units into chemiluminescent units per milliliter (CU/ml). In accordance with the manufacturer’s recommendations, results ≥10 CU/ml were considered as positive.

The anti-PLA2R ELISA and RC-IFA (both EUROIMMUN) were performed and evaluated as described before using the manufacturer’s cutoff values.6

Statistics

Data were evaluated statistically using GraphPad Prism (GraphPad Software Inc., La Jolla, CA). Confidence intervals (95% CI) were calculated according to the modified Wald method. To examine the discriminatory ability of the assays, receiver operating characteristics curve analysis was carried out. Cohen’s kappa test was performed to analyze the agreement between portions, with kappa (κ) values corresponding to almost perfect (0.81–1.00), substantial (0.61–0.80), moderate (0.41–0.60), fair (0.21–0.40), slight (0.01–0.20), and no (≤0) agreement. Spearman’s rank correlation test was used to determine the degree of correlation between assays. P values <0.05 were considered significant.

RESULTS

Diagnostic Performance Characteristics of ChLIA, ELISA, and RC-IFA

Clinical sensitivity and specificity were assessed in 155 patients with biopsy-proven pMN and 154 disease...
controls, respectively. The ChLIA was capable of detecting anti-PLA2R autoantibodies in 16 additional patients compared with ELISA and 1 additional patient compared with RC-IFA, who was positive by Western blot and biopsy staining (Supplementary Table S1). Thus, the ChLIA demonstrated a higher sensitivity (83.9%) for diagnosing pMN than ELISA (73.5%) and equalled RC-IFA (83.2%). Specificity was similarly high, ranging between 99.4% (ChLIA) and 100% (ELISA, RC-IFA). Only 1 control sample (minimal change disease) yielded discrepant qualitative results, showing anti-PLA2R reactivity exclusively by ChLIA with antibody levels only marginally above the cutoff; this patient was negative for PLA2R staining in the biopsy (Table 2, Figure 1). Among the 41 pMN samples that tested negative by ELISA, anti-PLA2R reactivity was detectable by ChLIA and RC-IFA in 16 (39.0%) and 15 (36.6%) cases, respectively, with most yielding results in the low to moderate positive range by ChLIA and RC-IFA (Supplementary Table S1).

Receiver operating characteristics curve analysis revealed high areas under the curve for ChLIA (0.899), ELISA (0.927), and RC-IFA (0.916), indicating similar discrimination between patients with pMN and disease controls. ChLIA and RC-IFA outperformed the ELISA in terms of the maximum sum of sensitivity and specificity and with regard to sensitivity at predefined specificities. The manufacturer’s cutoff (10 CU/ml) of the novel ChLIA lies slightly above the optimal cutoff (9.1 CU/ml), ensuring a specificity >99% (Table 3, Supplementary Figure S1).

Correlation Between ChLIA and ELISA

High overall concordance was found between qualitative anti-PLA2R results obtained by ChLIA and ELISA, as reflected by an agreement of 94.5% (95% CI: 91.3%–96.6%) and a K-value of 0.885 (95% CI: 0.833–0.938). A total of 114 samples (all pMN) were positive and 178 (25 pMN, 153 controls) negative by both methods (Figure 2). Seventeen samples (16 pMN, 1 minimal change disease) yielded discrepant results, that is, all of them reacted positively by ChLIA, whereas ELISA reactivity was in the borderline range in 4 cases and negative in 13 cases. Spearman’s rank correlation analysis revealed a significant correlation between both assays ($r = 0.978$, 95% CI: 0.969–0.984, $P < 0.001$; Figure 3a).

The analytical imprecision expressed as coefficients of variation for positive, and near cutoff samples were calculated as within-run coefficients of variation (2.1%–6.5%) and total coefficients of variation (5.0%–10.3%) (Supplementary Table S2). These results were similar to repeatability and reproducibility of the ELISA.

Correlation Between ChLIA and RC-IFA

The anti-PLA2R ChLIA and RC-IFA yielded concordant results in 99.4% (95% CI: 97.5%–100%) of cases, with a K-value of 0.987 (95% CI: 0.968–1.000), indicating almost perfect agreement. A total of 129 samples (all pMN were positive and 178 (25 pMN, 153 controls) negative by both methods (Figure 2). There were only 2 samples (1 pMN, 1 minimal change disease) with divergent qualitative results, both showing low positive ChLIA reactivity, whereas RC-IFA was negative. The Spearman’s rank coefficient indicated strong correlation between ChLIA results and RC-IFA titers ($r = 0.894$, 95% CI: 0.856–0.923, $P < 0.001$; Figure 3b).

**DISCUSSION**

The present study investigated the diagnostic performance of a novel anti-PLA2R ChLIA in comparison

---

**Table 2. Clinical sensitivity and specificity of the Anti-PLA2R ChLIA, ELISA, and RC-IFA**

| Panel        | $n$ | Anti-PLA2R ChLIA (cutoff 10 CU/ml) | Anti-PLA2R ELISA (cutoff 20 RU/ml) | Anti-PLA2R RC-IFA (cutoff titer 1:10) |
|--------------|-----|----------------------------------|-----------------------------------|--------------------------------------|
| pMN          | 155 | 130                              | 114                               | 129                                  |
| Sensitivity  | 83.9% (77.2%–88.9%) | 73.5% (66.1%–79.9%) | 83.2% (76.5%–88.3%) |
| IgAN         | 6   | 0                                | 0                                 | 0                                    |
| FSGS         | 10  | 0                                | 0                                 | 0                                    |
| MPGN         | 10  | 0                                | 0                                 | 0                                    |
| MCD          | 17  | 1                                | 0                                 | 0                                    |
| LN I–V       | 33  | 0                                | 0                                 | 0                                    |
| LN V         | 34  | 0                                | 0                                 | 0                                    |
| SLE          | 34  | 0                                | 0                                 | 0                                    |
| Specificity  | 99.4% (96.1%–100%) | 100% (97.1%–100%) | 100% (97.1%–100%) |

Anti-PL2A2, anti-phospholipase A2 receptor; ChLIA, chemiluminescence immunoassay; CI, confidence interval; CU/ml, chemiluminescent units per milliliter; ELISA, enzyme-linked immunosorbent assay; FSGS, focal segmental glomerular sclerosis; IgAN, IgA nephropathy; LN, lupus nephritis; MCD, minimal change disease; MPGN, membranoproliferative glomerulonephritis; pMN, primary membranous nephropathy; RC-IFA, recombinant cell-based indirect immunofluorescence assay; RU, relative units; SLE, systemic lupus erythematosus; sMN, secondary membranous nephropathy.

*a*Cutoff recommended by the manufacturer.

*b*Borderline results (≥14 to <20 RU/ml) were considered as negative.
Figure 1. Anti-phospholipase A2 receptor (anti-PLA2R) reactivity as determined in 155 patients with primary membranous nephropathy (pMN) and in 154 disease controls using (a) chemiluminescence immunoassay (ChLIA), (b) enzyme-linked immunosorbent assay (ELISA), and (c) recombinant cell-based indirect immunofluorescence assay (RC-IFA). To avoid excessive overlap of data points at the distinct titer classes (negative, 1:10, 1:32, 1:100, 1:320, 1:1000), the results of RC-IFA are indicated as absolute frequencies. Dashed lines represent the cutoff values for positivity. CU/ml, chemiluminescent units per milliliter; FSGS, focal segmental glomerular sclerosis; IgAN, IgA nephropathy; LN, lupus nephritis; MCD, minimal change disease; MPGN, membranoproliferative glomerulonephritis; RU, relative units; SLE, systemic lupus erythematosus; sMN, secondary membranous nephropathy.
with the established ELISA and RC-IFA. The clinical sensitivity of the ChLIA exceeded that of ELISA and RC-IFA by 10.4% and 0.7%, respectively, at similar specificities (>99%). The anti-PLA2R-positive rates detected by ChLIA (83.9%), ELISA (73.5%), and RC-IFA (83.2%) were equal to or higher than the prevalence data determined among non-preselected patients with pMN by different methods, such as Western blot (53.0–81.7%),10,11 RC-IFA (48.0–82.3%),12,13 ELISA (50.0–71.8%),14,15 addressable laser bead immunoassay (51.5–66.9%),16,17 luciferase immunoprecipitation systems assay (53.3%),18 and time-resolved fluoroimmunoassay (71.0–89.7%).19,20 These variations may be due to differences in assay techniques (e.g., epitope exposure, cutoff values, detected Ig subclass) and cohort characteristics (e.g., ethnicity, immunosuppressive treatment). Recently, Burbelo et al.18 reported a quantitative PLA2R-NanoLuc luciferase immunoprecipitation system assay that provides high diagnostic performance (receiver operating characteristics area under the curve = 1.0) and is, just like the novel ChLIA, more sensitive in detecting anti-PLA2R seropositivity than the ELISA. In the respective pMN panels, luciferase immunoprecipitation system found 1 and ChLIA found 16 additional anti-PLA2R–positive samples compared with ELISA.

Most published studies using the EUROMMUN anti-PLA2R ELISA adopted the manufacturer-recommended cutoff (20 relative units [RU]/ml), resulting in specificities ranging between 89.7% and 100%.7,14,16,21–24 However, some studies used customized thresholds to increase sensitivity, sometimes leading to adverse effects on specificity.16,21,22,24 In the present study, receiver operating characteristics analysis revealed an optimum cutoff value of 3.0 RU/ml (maximum sum sensitivity and specificity). Applying this cutoff, 17 additional pMN samples would have been positive by ELISA (sensitivity 84.5%), whereas specificity would fall from 100% to 96.8%, which we consider unacceptable. Bobart et al.25 recommended for centers preferentially performing ELISA, that samples giving ELISA values in the range between ≥2 and ≤20 RU/ml should be confirmed by RC-IFA owing to higher assay sensitivity.

In conclusion, the novel ChLIA is superior to ELISA in detecting autoantibodies against PLA2R, indicating its capability to improve diagnosis and follow-up testing of pMN. Its performance characteristics hold the potential for overcoming the sensitivity gap that exists between the established ELISA and RC-IFA, without compromising specificity. Fully automated random-access processing allows for rapid turnaround times and the option to incorporate the ChLIA into testing lines, giving laboratories with different requirements a higher degree of flexibility in their routines.

### DISCLOSURE

CD and SS are employees and WS is a board member of EUROMMUN. EUROMMUN is exclusive licensee of patents pertaining to the detection of autoantibodies to PLA2R. All the other authors declared no competing interests.
ACKNOWLEDGMENTS

The authors gratefully acknowledge Janine Stockdreher, Martina Lehmann, Sarah Konitzer, and Christine Maaßen for excellent technical assistance, and Alexander Kühnl for support in scientific communication. PR is a recipient of European Research Council ERC-2012-ADG-20120314 grant 322947 and 7th Framework Programme of the European Community contract 2012-305608 (European Consortium for High-Throughput Research in Rare Kidney Diseases), and the National Research Agency grant MNaims (ANR17-CE17-0012-01). We are greatly indebted to the clinicians who took care of the patients in the Department of Nephrology and Dialysis at Tenon Hospital, Paris, over the past 20 years. We thank Eva Cômeprat and all staff members of the Tenon Hospital Biological Resource Center (BRC CANCER HUEP-Paris) for their help in centralizing and managing biological data collection.

SUPPLEMENTARY MATERIAL

Supplementary File (Word)

Figure S1. Assay comparison using receiver operating characteristics (ROC) curve analysis for the discrimination between patients with pMN (n = 155) and disease controls (n = 154). The diagonal line indicates no discrimination (area under the curve: 0.5).

Table S1. Reactivity in anti-PLA2R ChLIA and RC-IFA among 41 pMN samples that tested negative by anti-PLA2R ELISA. Positive results are highlighted.

Table S2. Coefficients of variation (CV) for the anti-PLA2R ChLIA. Five representative samples with target values covering the positive and near cutoff measuring range were
used to determine anti-PLA2R levels using the newly developed ChLIA. CV = SD/mean expressed as a percentage.

REFERENCES

1. Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12:983–997.
2. De Vriese AS, Glasscock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28:421–430.
3. Schlumberger W, Hornig N, Lange S, et al. Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1. Autoimmun Highlights. 2014;13:108–113.
4. Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient’s care. Lancet. 2015;385:1983–1992.
5. Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A(2)-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26:2526–2532.
6. Dähnrich C, Komorowski L, Probst C, et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta. 2013;421:213–218.
7. Li X, Wei D, Zhou Z, et al. Anti-PLA2R antibodies in Chinese patients with membranous nephropathy. Med Sci Monit. 2016;22:1630–1636.
8. Cinquanta L, Fontana DE, Bizzaro N. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? Auto Immun Highlights. 2017;8:9.
9. Debiec H, Ronco P. Immunopathogenesis of membranous nephropathy: an update. Semin Immunopathol. 2014;36:381–397.
10. Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22:1137–1143.
11. Akiyama S, Akiyama M, Imai E, et al. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol. 2015;19:653–660.
12. Wei SY, Wang YX, Li JS, et al. Serum anti-PLA2R antibody predicts treatment outcome in idiopathic membranous nephropathy. Am J Nephrol. 2016;43:129–140.
13. Kimura Y, Miura N, Debiec H, et al. Circulating antibodies to alpha-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy. Clin Exp Nephrol. 2017;21:117–126.